 |
市場調查報告書
口服糖尿病治療藥的全球市場(2020年∼2027年)Global Oral Anti Diabetes Drugs Market - 2020-2027 |
||||||
| 出版商 | DataM Intelligence | 商品編碼 | 965965 | ||||
| 出版日期 | 按訂單生產 | 內容資訊 | 英文 商品交期: 請詢問到貨日 |
||||
| 價格 |
|
||||||
| 口服糖尿病治療藥的全球市場(2020年∼2027年) Global Oral Anti Diabetes Drugs Market - 2020-2027 | ||
| 出版日期: 按訂單生產 | 內容資訊: 英文 |
|
全球口服糖尿病治療藥市場成長，由於老年人口的增加，政府舉措的增加，及製藥企業的持續性研究開發等受到推動。
該市場的大幅度成長，是起因於糖尿病的盛行率的上升，及健康意識相關的各種醫療機關開始的計劃數增加等要素。現在，糖尿病病例整體約有10％是第一型，其餘是2型。第二型糖尿病的盛行率上升的話，對糖尿病治療藥有產生龐大需求的可能性。
但，口服糖尿病治療藥的高成本和替代解決方案的持續性妨礙市場成長。還有藥物費大幅度上升，胰島素的偏好，藥物相關的併發症等，預計抑制今後數年的市場擴大。
本報告提供全球口服糖尿病治療藥市場的相關調查，市場機會，成長及阻礙因素，COVID-19大流行的影響，各藥物類別、用途類型、流通管道、地區的市場分析，競爭情形，主要企業的簡介等資訊。
The global oral anti diabetes drugs market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Diabetes is a chronic disease that occurs when the body cannot effectively use the produced insulin or the pancreas does not produce sufficient insulin. The pancreas is an organ that sits behind the stomach and releases hormones into the digestive system. Diabetes is categorized by increased levels of blood glucose, which can cause severe damage to blood vessels, heart, kidneys, nerves, and eyes. Diabetes is of two types: type 1 and type 2. Type 1 diabetes, also known as juvenile diabetes or insulin-dependent diabetes, arises when the immune system misguidedly attacks and kills the beta cells of the pancreas. Type 2 diabetes arises when the body cannot appropriately use the insulin that is released or does not make enough insulin. About 90% of people with diabetes have type 2 diabetes. Over the recent years, oral anti-diabetes drug has been witnessing considerable growth on the back of rising incidences of diabetes. This factor is driving the growth of the market in the forecast period.
The global oral anti diabetes drugs market growth is driven by the growing geriatric population, growing government initiatives, and continuous research and development conducted by pharmaceutical manufacturers.
The rising prevalence of diabetes worldwide is likely to create a vast demand
The significant growth in the market can be attributed to factors such as the rising prevalence of diabetes and the increasing number of programs initiated by various health organizations related to health awareness. In 2019, it was estimated that out of 511 million people suffering from diabetes, 31.3% were undiagnosed. In 2019, diabetes was the cause of 4.2 million deaths per year, making it the eighth leading cause of death, worldwide. The diabetic condition, on the whole, doubles the risk of death. Currently, about 10% of all diabetes cases are Type-1 and the remaining are of Type-2. Thus, the rise in the prevalence of type-2 diabetes worldwide is likely to create a vast demand for diabetes drugs..
Sedentary lifestyles & rise in cases of diabetes to leverage market revenue
Inactive lifestyle, obesity, and higher stress along with growing occurrence of diabetes are anticipated to boost the demand for oral anti-diabetic drugs over the forecast period. Apart from this, technological breakthroughs and medical compensation facilities are likely to impel the growth of oral anti-diabetic drug market in the years ahead. Nevertheless, the increase in the R&D activities and tremendous potential for oral anti-diabetic drug market to grow will chart a profitable roadmap for the business over the forecast period, thereby normalizing the negative impact of hindrances on the oral anti-diabetic drug market
High cost of oral anti diabetes drugs and persence of alternate solution is hinder the market growth
The gigantic rise in the drug costs, however, is projected to restrict the expansion of oral anti-diabetic drug market in the forthcoming years. Also, preferred use of insulin over oral anti diabetes drugs and the complications associated with the drugs has been hindering the market growth.
COVID-19 Impact Analysis
Covid-19 pushes up sales of oral anti diabetes drugs. Patients given these drugs had a mortality rate of 18 percent as compared with 37 percent in matched patients receiving only insulin according to the study involved seven Italian hospitals during the first surge of COVID cases last spring. The pandemic is seems to impacting the operation of pharmaceutical companies with those dealing in oral anti diabetes drugs. Diabetics severely had turned people into buying more of medicines for these ailments. In the month of June, demand for Anti-Diabetic segment grew at 12.7 per cent yoy due to continued buying during the period of the lockdown. Thus, the pandemic has incresed the sale and ultimately growth of the oral anti diabetes drugs market in the forecast period.
By drug class, the oral anti diabetes drugs market is classified into sulfonylureas (gliclazide, glyburide, glimepiride, others), meglitinides (biguanides, metformin, repaglinide, nateglinide, others), biguanides (alpha-glycosidase inhibitors, voglibose, acarbose, others), DPP-4 Inhibitors, others.
DPP-4 Inhibitors segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
The Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors segment has the largest market share in the forecast period. DPP-4 inhibitor drugs are gaining momentum in the market because the products do not seem to have any effect on primary adverse cardiovascular outcomes and risk for heart failure. Besides, they can be used both as a combination therapy with insulin, sulphonylureas, and dipeptidyl peptidase-4 drugs and as a monotherapy, thus, making it a widely used class of drugs. During the forecast period, the DPP-4 inhibitors segment is expected to witness constant growth rate, due to the introduction of new drugs that have improved efficacy, like glucagon-like peptide (GLP-1) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors. The segment is still expected to maintain the largest market share among all oral anti-diabetes drugs market segments.
The sulfonylureas segment has the second largest market share in the forecast period. These are sometimes called "oral hypoglycemic agents," work very differently than metformin. They signal the pancreas to release insulin and they also help the body's cells use insulin better. Sulfonylureas may be old, but they're effective. They can lower A1C levels (a measure of blood sugar control over the previous 2-3 months) by 1% to 2%. The affordability and higher glucose-lowering efficacy are possible advantages that explain why this drug class is frequently used in practice. However, concerns have been raised for why sulfonylureas should not be used as first-line therapy, and should be avoided in use with metformin, due to concerns regarding severe cardiovascular and hypoglycemic risk.
Sulfonylureas are classified into two generations, first-generation and second-generation. Currently used are the second-generation sulfonylureas (Glyburide, Glipizide, Glimepiride, Glicazide), while the first-generation sulfonylureas are no longer used (Tolbutamide, Chlorpropamide, Tolazamide) due to severe hypoglycemia episodes. This drug class is typically used for patients with type 2 diabetes where cost is a major issue, patients who are not overweight, and for whom metformin is contraindicated, not well tolerated, or has failed to meet glycemic target goals. The most common adverse effects of sulfonylureas are hypoglycemia, weight gain, and risk for cardiovascular events. Clinicians initially prescribe lower doses of sulfonylureas to prevent the risks of hypoglycemia. Unfortunately, in some patients taking sulfonylureas, the adverse effects may outweigh the benefits.
Glicazide: Gliclazide is used in the treatment of type 2 diabetes mellitus. It is used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It is an antidiabetic medication. It works by increasing the amount of insulin released by the pancreas in order to lower the blood sugar levels. Gliclazide may also be called by the brand names Bilxona, Dacadis, Diamicron, Laaglyda, Nazdol, Vamju, Vitile, Ziclaseg and Zicron.
Glipizide: Glipizide is an oral diabetes medicine that helps control blood sugar levels by helping your pancreas produce insulin. Glipizide is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Glipizide oral tablet is available as the brand-name drugs Glucotrol and Glucotrol XL. It's also available as a generic drug. Generic drugs usually cost less. In some cases, they may not be available in every strength or form as the brand.
Glyburide : Glyburide oral tablet comes as brand-name drugs and as a generic drug. Brand names: Diabeta, Glynase PresTabs. Glyburide oral tablets come in two forms: regular and micronized. The micronized tablets contain smaller particles of the drug. Glyburide is used along with diet and exercise, and sometimes with other medications, to treat type 2 diabetes. Glyburide is in a class of medications called sulfonylureas. Glyburide lowers blood sugar by causing the pancreas to produce insulin.
Geographical Analysis
North America region holds the largest market share global oral anti diabetes drugs market
North America region is dominating the global oral anti diabetes drugs market accounted for the largest market share in 2019, owing to the large investment in healthcare and pressing schedules and unhealthy eating habits of people, primarily in the U.S. is said to be driving the market in the region. In addition, growing sedentary lifestyle, presence of diabetes medicines in the Essential drug List of the nations and wide insurance coverage for diabetes drugs have contributed to the growth rate of Oral anti-diabetes drugs in the region. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period. This is due to the high prevalence of diabetes in this region, which caused consequent adverse health and economic consequences. The rates of newly diagnosed cases of Type 1 and Type 2 diabetes are increasing among the youth in the Asia-Pacific region. In 2019, China and India, around 123.6 million people and 76.79 million people, respectively, are living with diagnosed diabetes. Moreover, an increase in the launch of new drugs with improved efficacy and high reimbursement for medicines is expected to have a positive impact on the oral anti-diabetes drug market. The increasing incidence and prevalence of diabetes and the increasing healthcare expenditure in the Asia-Pacific countries are an indication of the increasing usage of oral anti-diabetes drugs.
The oral anti diabetes drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Glenmark Pharma, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck, GlaxoSmithKline, Piramal Healthcare, Bristol-Myers Squibb, Bayer Healthcare, Dr. Reddy's Laboratories Ltd, and Pfizer. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the oral anti diabetes drugs market globally.
Glenmark Pharma
Overview: Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.
Product Portfolio: The Company's portfolio comprised 164 products including of API business, an independent subsidiary called Glenmark Life Sciences, Glenmark Pharmaceuticals is focused in the areas of respiratory and dermatology.
Key Development: In April 2019, Glenmark Pharma launch of its anti-diabetes drug Remogliflozin in India. "Glenmark is the first company in the world to launch the novel SGLT2 inhibitor Remogliflozin and India is the first country to get access to this innovative drug. The drug is indicated in the treatment of type-2 diabetes mellitus in adults.
The global oral anti diabetes drugs market report would provide an access to an approx. 67 market data table, 56 figures and 300 pages.
LIST NOT EXHAUSTIVE
